Active, not recruitingPhase 3NCT04384484
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ADC Therapeutics S.A.
- Intervention
- Loncastuximab Tesirine(drug)
- Enrollment
- 440 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2028
Study locations (30)
- University of California San Diego Moores Cancer Center, La Jolla, California, United States
- Redlands Community Hospital, Redlands, California, United States
- The Oncology Institute of Hope and Innovation, Whittier, California, United States
- Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
- UnityPoint Health - Iowa Oncology Research Association (IORA), Des Moines, Iowa, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Comprehensive Cancer Centers of Nevada - Henderson, Las Vegas, Nevada, United States
- Kaiser Permanente Interstate Medical Office Central, Portland, Oregon, United States
- Hollings Cancer Center, Charleston, South Carolina, United States
- Virginia Cancer Specialists, Gainesville, Virginia, United States
- Medical College of Wisconsin Cancer Center Clinical Trials Office, Milwaukee, Wisconsin, United States
- Clinica Adventista Belgrano, Belgrano, Buenos Aires, Argentina
- Clínica de Nefrología, Urología y Enfermedades Cardiovasculares S.A., Santa Fe, Buenos Aires, Argentina
- Instituto Médico Especializado Alexander Fleming, Buenos Aires, Distrito Federal, Argentina
- Grupo Gamma - Hospital Privado Rosario, Rosario, Santa Fe Province, Argentina
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04384484 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.